Evidence map›Paper›PMID 14722605›Full record

ReviewThe Journal of clinical investigation2004

Telomeres, stem cells, senescence, and cancer.

Norman E Sharpless, Ronald A DePinho

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The Journal of clinical investigation, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02985658 (Expanded Access Protocol With ABT-888), which is not on this map. Cited by 174 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
174citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02985658 no longer availablenot on this map

Expanded Access Protocol With ABT-888 (Veliparib) in Patients With Metastatic BRCA-Mutation Associated or Triple Negative Breast Cancer

Typeexpanded_accessSponsorUniversity of WashingtonConditionsMetastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation, Triple-Negative Breast CancerArmsVeliparib, Cisplatin, Vinorelbine
3 · Its place in the literature

Who cites it

174 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Consequences of Aging on Bone.Aging and disease · 2023
    Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. In search of elixir: Pharmacological agents against stem cell senescence.Iranian journal of basic medical sciences · 2021
    Review
  17. Article
  18. Review
  19. Review
  20. Review

114 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Norman E SharplessDepartment of Medicine and Genetics, Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599-8212, USA. nes@med.unc.edu
Ronald A DePinho

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mammalian aging occurs in part because of a decline in the restorative capacity of tissue stem cells. These self-renewing cells are rendered malignant by a small number of oncogenic mutations, and overlapping tumor suppressor mechanisms (e.g., p16(INK4a)-Rb, ARF-p53, and the telomere) have evolved to ward against this possibility. These beneficial antitumor pathways, however, appear also to limit the stem cell life span, thereby contributing to aging.

Indexed as

ApoptosisCellular SenescenceAgingAnimalsGenes, Tumor SuppressorHumansModels, BiologicalModels, GeneticMutationNeoplasmsStem CellsTelomeraseTelomereTelomerase

Identifiers

PMID14722605
PMCPMC311439

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.